Johns Hopkins University

CompanyUnited StatesFounded 1876

ROROpenAlexWikidata

Johns Hopkins University develops one asset, in phase 2 (pegsebrenatide in Parkinson's disease). Mostly peptide acting on GLP1R; based in the United States, founded in 1876.

1
Asset
Furthest stage
Phase 2
1,575
Grants
412
Trials
55
Signals

Pipeline

1
  • pegsebrenatide

    Activates GLP-1 receptors to suppress microglial activation and neuroinflammation.

    Phase 2, Peptide, GLP1R, Parkinson's disease, multiple sclerosis

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Trials523
  • Deals1
  • People24
  • Signals20
  • Integrity notices10
  • Similar companies6

Papers

Intelligence